{"organizations": [], "uuid": "206f711a208e413535ad70a84a983530a3852227", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-teva-pharm-ceo-cfo-comments-on-201/brief-teva-pharm-ceo-cfo-comments-on-2018-outlook-idUSJ7N1NL005", "country": "US", "domain_rank": 408, "title": "BRIEF-Teva Pharm CEO, CFO comments on 2018 outlook", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-08T16:01:00.000+02:00", "replies_count": 0, "uuid": "206f711a208e413535ad70a84a983530a3852227"}, "author": "", "url": "https://www.reuters.com/article/brief-teva-pharm-ceo-cfo-comments-on-201/brief-teva-pharm-ceo-cfo-comments-on-2018-outlook-idUSJ7N1NL005", "ord_in_thread": 0, "title": "BRIEF-Teva Pharm CEO, CFO comments on 2018 outlook", "locations": [], "entities": {"persons": [{"name": "steven scheer", "sentiment": "none"}, {"name": "schultz", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "teva", "sentiment": "none"}, {"name": "teva pharmaceutical industries ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 8, 2018 / 2:02 PM / in 14 minutes BRIEF-Teva Pharm CEO, CFO comments on 2018 outlook Reuters Staff 1 Min Read \nFeb 8 (Reuters) - Teva Pharmaceutical Industries Ltd : \n* TEVA CEO SCHULTZ: HALF OF EXPECTED REVENUE DECLINE IN 2018 DUE TO GENERIC COMPETITION TO COPAXONE \n* TEVA CEO SCHULTZ: OPTIMISTIC TEVA WILL CONTINUE TO REDUCE ITS DEBT LEVELS \n* TEVA CEO SCHULTZ: TEVA REDUCED DEBT BY $1.1 BILLION SINCE END OF 2017 \n* TEVA CFO: COPAXONE SALES ESTIMATED AT $1.8 BILLION IN 2018 \n* TEVA CFO SEES GENERIC PROAIR COMPETITION IN SECOND HALF OF 2018 \n* TEVA CFO SEES SECOND GENERIC 40 MG COPAXONE AS EARLY AS APRIL * TEVA CFO: GROSS DEBT TO FALL BY $3.5 BILLION IN 2018 \n* TEVA CEO: TEVA WILL NO LONGER GIVE SPECIFIC NUMBERS ON PRICE EROSION \n* TEVA CFO: MAY LOOK FOR FURTHER ASSET DIVESTMENTS IN 2018 TO PAY DOWN DEBT Further company coverage: (Reporting by Steven Scheer)", "external_links": [], "published": "2018-02-08T16:01:00.000+02:00", "crawled": "2018-02-08T16:20:55.004+02:00", "highlightTitle": ""}